Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a clinical-stage TechBio company that regularly issues news and updates about its platform, pipeline and partnerships. As a biotechnology company focused on decoding biology to radically improve lives, Recursion generates announcements that span clinical trial readouts, business development milestones and technology advances related to its Recursion OS.
News for RXRX often highlights progress in clinical programs, such as the TUPELO Phase 1b/2 trial of REC-4881 in familial adenomatous polyposis (FAP), the ELUCIDATE Phase 1/2 trial of REC-617 in advanced solid tumors and ovarian cancer, and the DAHLIA Phase 1/2 study of REC-1245 in solid tumors. Company communications describe efficacy, safety, and design details for these studies, as well as plans for future data readouts and regulatory interactions.
Investors also see frequent updates on partnerships and collaborations. Recursion reports milestones from its long-term collaboration with Genentech and F. Hoffmann-La Roche Ltd, including acceptance of whole-genome phenotypic maps such as a microglia map, and from its multi-target collaboration with Sanofi in oncology and immunology. These items often include information about milestone payments and the scope of ongoing discovery work.
Additional RXRX news covers financial results and capital markets activity, such as quarterly earnings releases, cash runway commentary, and disclosures related to registration statements and share issuances connected to collaborations or acquisitions. The company also announces participation in healthcare and investor conferences, webinars on clinical data, and leadership changes, including CEO transition plans.
By following the RXRX news feed, readers can track how Recursion’s Recursion OS platform is being applied across its internal pipeline and partnered programs, as well as how business decisions, collaborations and governance developments may shape the company’s trajectory in the TechBio and biotechnology sectors.
Recursion (NASDAQ: RXRX) announced that on February 6, 2026 its Compensation Committee approved inducement restricted stock unit awards covering 820,431 shares of Class A common stock granted to 17 new employees under the 2024 Inducement Equity Incentive Plan.
Each RSU vests 25% at the first quarterly vesting date on or after the one-year anniversary of the vesting commencement date, then vests at 1/16th each quarter thereafter, subject to continued employment and plan/grant agreement terms. Grants were made pursuant to Nasdaq Listing Rule 5635(c)(4).
Recursion (Nasdaq: RXRX) announced that CEO & President Najat Khan, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 10:30am PT in San Francisco.
Management will also participate in the 28th Annual Needham Growth Conference on Friday, January 16, 2026. Webcasts will be available in the events section of Recursion Investor Relations at ir.recursion.com.
Recursion (NASDAQ: RXRX) reported positive Phase 1b/2 TUPELO results for REC-4881 in familial adenomatous polyposis (FAP) on Dec 8, 2025. REC-4881 (4 mg QD) produced a 43% median polyp-burden reduction at 12 weeks (n=12) with 75% of evaluable patients showing reductions. At Week 25—12 weeks after stopping therapy—82% (9 of 11) maintained reductions with a 53% median decrease from baseline. Safety was consistent with MEK1/2 inhibition: mostly Grade 1–2 TRAEs, 15.8% Grade 3, and no Grade ≥4 reported. Natural-history data showed 87% of similar untreated FAP patients had annualized polyp increases (n=55). Next steps include FDA engagement in 1H26 and population/dosing expansion.
Recursion (Nasdaq: RXRX) will host a webinar on December 8, 2025 to present an updated clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in familial adenomatous polyposis (FAP).
The live webinar is scheduled for 8:00 AM ET / 6:00 AM MT / 1:00 PM GMT and will stream on Recursion's X, LinkedIn, and YouTube channels. The session is titled: Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy in Familial Adenomatous Polyposis (FAP): Updated Safety and Efficacy.
Presenters include Najat Khan, Ph.D. (incoming CEO and President), David Mauro, M.D., Ph.D., Beth Bruckheimer, Ph.D., Jessica Stout, D.O., and Alfred Cohen, M.D.
Recursion (Nasdaq: RXRX) reported Q3 2025 results and a business update on Nov 5, 2025, highlighting a $30 million milestone from Roche/Genentech for a microglia whole-genome phenomap and surpassing $500 million in cumulative partner upfronts and milestones. Cash and cash equivalents were $667.1M as of Sept 30, 2025 and approximately $785M as of Oct 9, 2025 (unaudited), with an expected runway through end of 2027 absent additional financing. Q3 revenue was $5.2M vs $26.1M year-ago; R&D expenses were $121.1M; net loss was $162.3M. Pipeline progress included REC-617 dose escalation, REC-7735 nominated as a development candidate, and REC-4881 data due Dec 2025.
Recursion (NASDAQ: RXRX) announced a Board‑approved leadership transition effective January 1, 2026. Najat Khan, Ph.D., currently Chief R&D and Commercial Officer and Board member, will become CEO and President while remaining on the Board. Co‑founder Chris Gibson, Ph.D. will transition from CEO to Chairman of the Board. Rob Hershberg, MD/Ph.D., current Chairman, will become Vice‑Chairman and Lead Independent Director. The Board cited continuity and execution as goals for advancing the OS platform, pipeline readouts, and commercialization priorities.
Recursion (Nasdaq: RXRX) announced participation in two upcoming investor conferences in November 2025. The company will present at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025 and at the Jefferies Global Healthcare Conference London on Tuesday, November 18, 2025. Webcasts will be available in the events section of Recursion's investor relations website at ir.recursion.com.
Recursion (Nasdaq: RXRX) will report third quarter 2025 business updates and financial results on Wednesday, November 5, 2025 before market open. The company will host a public (L)earnings call at 8:00 AM ET / 6:00 AM MT / 1:00 PM GMT.
The live stream will be broadcast on Recursion’s X, LinkedIn, and YouTube channels. Investors, analysts, and the public can submit questions in advance via the company’s online form at the provided link.
Recursion (NASDAQ:RXRX), a clinical stage TechBio company, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Citi 2025 BioPharma Back to School Conference on September 3 and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8. Investors can access the webcasts through Recursion's investor relations website at ir.recursion.com.
Recursion (NASDAQ:RXRX) reported Q2 2025 financial results and business updates. The clinical-stage TechBio company achieved a $7 million milestone payment from Sanofi and provided updates on key clinical programs. Revenue reached $19.2 million, up from $14.4 million in Q2 2024, while net loss widened to $171.9 million from $97.5 million year-over-year.
The company highlighted progress in its clinical pipeline, including REC-1245 (RBM39 degrader) and REC-617 (CDK7 inhibitor). Cash position stood at $533.8 million, with runway expected into Q4 2027. Recursion continues advancing partnerships with Sanofi, Roche/Genentech, Bayer, and Merck KGaA, while expanding its Recursion OS 2.0 platform capabilities.
The company announced a restructuring plan with expected costs of $9.3 million for 2025.